Streetbeat News

Stock Prices

MS

Market whales have shown a mixed sentiment on Morgan Stanley (NYSE:MS) options, with a bearish lean. Benzinga's options scanner revealed 14 unusual trades, indicating a price target range of $85.0 to $105.0. The volume and open interest in MS options have been notably high, with significant trades including both calls and puts. Morgan Stanley's stock is currently up by 0.91% at $95.65, with potential overbought signals and earnings expected in 70 days.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 5:30 pm

CGNX

HSBC analyst Helen Fang upgrades Cognex (NASDAQ:CGNX) from Hold to Buy and sets a new price target of $52.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 5:25 pm

DIS

IWM

PLTR

TLT

US stocks are on track for a fourth consecutive session of gains despite hawkish comments from Fed's Kashkari, with the S&P 500, Nasdaq 100, and Dow Jones all seeing modest increases. Treasury yields fell, boosting bond ETFs like TLT. Palantir and Disney shares tumbled following disappointing guidance and performance, respectively. Other notable stock movements were influenced by earnings reports and rumors of partnerships.

Portfolio Pulse from Piero Cingari

May 07, 2024 | 5:18 pm

BKNG

Deep-pocketed investors show a bullish sentiment towards Booking Holdings (NASDAQ:BKNG), with options trading activity indicating a focus on a price band between $2000.0 and $4250.0. The analysis of options over the last month reveals a mix of bullish and bearish trades, with a higher total trade price for calls. Booking Holdings, the world's largest online travel agency, has seen its stock price slightly decrease by -0.25% to $3589.41, with analysts giving an average price target of $3946.0.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 5:16 pm

MRNA

Deep-pocketed investors have shown a significant interest in Moderna (NASDAQ:MRNA), with a split sentiment of 50% bullish and 41% bearish among them. Benzinga's tracking of public options records revealed 12 extraordinary options activities, indicating a targeted price range for Moderna between $90.0 and $180.0 over the last 3 months. The trading volume of MRNA is up by 0.56%, with a current price of $122.82, and its next earnings report is scheduled in 86 days. Moderna's mRNA technology has been rapidly validated with its COVID-19 vaccine, and it has 39 mRNA development candidates in clinical trials.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 5:16 pm

DKNG

DraftKings (NASDAQ:DKNG) has seen a significant options trading activity, indicating a mixed sentiment among investors, with 60% bearish and 40% bullish. The trading volume and open interest in options suggest a target price range of $23.0 to $50.0. DraftKings, a leader in online sports and casino gambling, is currently live in 24 states for sports betting and 7 for iGaming. Despite a slight decrease in stock price to $44.01, professional analysts have set a consensus target price of $54.4, with ratings ranging from Buy to Overweight.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 5:16 pm

DJT

Trump Media & Technology Group Corp. (NASDAQ:DJT) shares are trading lower after the company announced the appointment of Semple, Marchal & Cooper, LLP as its new independent registered public accounting firm, effective May 4, 2024. This follows charges of 'massive fraud' by the SEC against the company's previous audit firm, BF Borgers CPA PC, and its owner. Additionally, Trump Media CEO Devin Nunes has accused certain brokerage firms of stock manipulation, leading to a letter addressed to various committees of the U.S. House of Representatives.

Portfolio Pulse from Nabaparna Bhattacharya

May 07, 2024 | 5:15 pm

REAX

Real Brokerage shares are trading higher after the company reported mixed Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 5:11 pm

FGEN

FibroGen, Inc. (NASDAQ:FGEN) shares rose after reporting Q1 financial results with sales exceeding analyst estimates but earnings missing expectations. The company highlighted strong sales growth, particularly from roxadustat in China, and a significant cash runway into 2026. Despite a year-over-year stock decrease, recent developments and upcoming clinical trial results could influence investor decisions.

Portfolio Pulse from Erica Kollmann

May 07, 2024 | 5:11 pm

BYON

Beyond, Inc. (NYSE:BYON) shares fell after reporting Q1 results that missed analyst expectations. The company reported a loss of $1.22 per share against an expected loss of 87 cents, and sales of $382.281 million versus the expected $389.264 million. Despite this, Beyond saw a 27% year-over-year increase in orders and a 26% increase in active customers. The company is focusing on building a profitable brand portfolio, aiming to transform its business model. Analysts have a mixed outlook, with an average 12-month price target of $37, suggesting potential upside.

Portfolio Pulse from Erica Kollmann

May 07, 2024 | 5:10 pm